Pierret T, Greillier L, Guisier F, Daniel C, et al. Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer 2025;209:108766.
PMID: 41039676